G ROUP A streptococcal infection initiates acute rheumatic fever; rheumatic valvular heart disease is a sequela that develops during or subsequent to the acute rheumatic episode. The mechanism by which the preceding streptococcal infection produces the arthritic and constitutional symptoms and valvular heart disease is unknown. Regardless of the mechanism involved, there is little doubt that prevention of the streptococcal infection eliminates acute rheumatic fever and presumably rheumatic heart disease in any population group. This fact has guided the management of a selected group of individuals, namely those patients who have already had 1 attack of rheumatic fever. The continuous prophylactic administration of a sulfonamide drug or penicillin is a widely practised measure for ensuring freedom from streptococcal infections and rheumatic recurrences.
The establishment of the relationship of the streptococcal infection to acute rheumatic fever led to the development of other methods for the control of rheumatic fever, since it was logical to believe that successful treatment of the original streptococcal respiratory disease might alter the attack rate of this nonsuppurative complication. Treatment with sulfonamides failed to prevent rheumatic fever" 2 in spite of the favorable influence it exerted on the natural course of the acute respiratory illness. Subsequently, penicillin was employed by Massell, Dow, and Jones3 for the therapy of streptococcal infections in patients who had experienced 1 or more rheumatic episodes and recurrent attacks of rheumatic fever were From the Departments of Pediatrics, Medicine and Preventive Medicine, Western Reserve University School of Medicine and City Hospital, Cleveland, Ohio.
This investigation was conducted under the sponsorship of the Commission on Streptococcal Diseases, Armed Forces Epidemiological Board, and was supported by the Office of The Surgeon General, Department of the Army, Washington, D. C., and Wyeth, Inc. 1144 eliminated. Similarly, initial attacks of rheumatic fever may be prevented by successful treatment of the streptococcal illness with penicillin or other antibiotics. 4 On the basis of this and other information, the American Heart Association' has made recommendations for the control of rheumatic fever that are summarized in table 1 . Minor changes in the methods employed in prophylaxis and treatment of streptococcal infections undoubtedly will be made as experience ac- cumulates. For example, the duration of protection afforded by various doses of benzathine penicillin has not been determined nor has the daily oral dose of penicillin prophylaxis been finally established. Recent evidence' indicates that 1,200,000 units of benzathine penicillin will protect against streptococcal infections for 6 weeks and 900,000 units for 4 weeks. Likewvise, oral penicillin probably should be administered in doses of 200,000 units twice daily to insure adequate prophylaxis.
It appears unlikely that major revisions in these recommendations will be made unless new data become available that invalidate previous conclusions. Recently, serious doubts have been raised as to whether successful treatment of streptococcal infections does indeed prevent valvular heart disease. In addition, some physicians have questioned the desirability of continuing prophylaxis for life in those individuals who have experienced 1 or more rheumatic attacks. It is the purpose of the present discussion to review some of the data and considerations presently available regarding these 2 aspects of the problem of rheumatic fever. Primarily on the basis of the above studies the American Heart Association made recommendations for the prevention of rheumatic fever. Until evidence to the contrary is produced, it was logical to assume that prevention of the acute joint and constitutional symptoms of rheumatic fever would result in a decreased incidence of rheumatic valvular heart disease.
Recently, Weinstein, Boyer, and Goldfield12 have produced some data that indicate that treatment of the preceding respiratory illness prevents the symptoms of acute rheumatic fever but not valvular heart disease. In their initial studies' electrocardiographic abnormalities developed in patients with scarlet fever during early and late convalescence and this was considered as evidence that rheumatic carditis was not prevented by therapy. Subsequent follow-up studies'2 confirmed this impression, since rheumatic valvular heart disease appeared in most of those patients who exhibited abnormalities and did not appear in those with normal electrocardiograms. In Weinstein's study'2 167 patients with scarlet fever were treated with penicillin. Forty of these received 800,000 units orally each day for 10 days; 127 were given 120,000 units intramuscularly daily for 10 11.2 per cent of 566 untreated controls subsequent to streptococcal pharyngitis. Treatment with penicillin or broad-spectrum antibiotics in 724 patients was associated with an incidence of these abnormalities of only 5.2 per cent, a highly significant difference. If the electrocardiographic changes are specific and indicate rheumatic carditis, the data obtained by Hahn22 would suggest that the incidence of specific carditis was decreased by treatment. It is also possible that treatment prevented only nonspecific changes rather than the abnormalities associated with rheumatic carditis.
A remarkable finding in the report of Weinstein12 is the very high incidence of valvular heart disease found 7 years later in the 10 patients with electrocardiographic abnormalities. That 8 of these 10 showed evidence of rheumatic heart disease at follow-up examination in contrast to none of those whose tracings 7 years earlier were normal suggests that these electrocardiographic changes presage the development of valvular heart disease with remarkable accuracy and that their absence is a reassuring prognostic sign. It is difficult to reconcile these results with studies on patients with symptoms of acute rheumatic fever. For example, Stolzer, Houser, and Clark23 studied 138 patients who had daily electrocardiograms for the first 3 weeks and every other day for the next 6 weeks. All patients were maintained on prophylaxis and examined 14 months later for evidence of valvular heart disease. Approximately 50 per cent of the group showed abnormal prolongation of A-V conduction during the course of acute rheumatic fever, and of this group only 38 per cent were found to exhibit valvular heart disease 14 months later. In contrast, 22 per cent of those patients who showed no abnormal atrioventricular conduction exhibited valvular heart disease at the time of the final examination. Thus, in this study abnormal prolongation of the P-R interval did not necessarily foretell the development of valvular heart disease and valvular abnormalities developed frequently in the absence of prolongation of the conduction time. In order to plan a rational method of management of the patient who has experienced rheumatic fever the physician should be acquainted with certain epidemiologic features of streptococcal infections and rheumatic fever. Group A streptococci are maintained in nature in the upper respiratory tract of man. The most dangerous source of infections is the carrier who has recently acquired the organism. 25 Since streptococcal infections occur frequently in the young, school-age child, any situation that places the individual in contact with children increases the risk of infection. The organism is transferred to the susceptible host by intimate contact and not by droplet nuclei, contaminated dust, bedding, and other articles. 25 Although adults apparently acquire fewer streptococcal infections than children, it is probably a fallacy to believe that this is due to acquired resistance. Immunity in man is typespecific and relatively long enduring. 25 26 Since most adults probably have had experience with only a few serologic types during childhood, they should become infected if adequately exposed to a carrier harboring a new type of streptococcus. Experience in military populations shows that young adults are very susceptible to these infections when assigned to an installation experiencing an epidemic.
Although type-specific immunity to streptococcal infections may play a minor role in the decreased incidence of both initial and recurrent attacks of rheumatic fever in older age groups, the major factor is most likely the lack of effective contacts with carriers of the organism. Another factor that may contribute to the low rates of initial attacks of rheumatic fever in the adult is decreased susceptibility to rheumatic fever following a streptococcal infection. ' 20.6 per cent in the first year following an attack, 10.7 per cent following 1 year of freedom from activity, and 6.6 per cent following 2 or more years of freedom. The recurrence rate in children was higher than in young adults. The annual recurrence rate for patients between 17 and 25 years of age was 3.7 per cent, a seemingly low risk; however, over a 10-year period the patient statistically had 1 chance in 3 of developing a recurrence.
Some information is available concerning the time that first recurrences of rheumatic fever occur. Comparison of the data from 2 studies34 35 shows considerable differences in the time the first recurrences developed (table 3) . These differences may be due to multiple factors, including length of observation of the rheumatic populations, age, and number of streptococcal infections. However, the important fact is that recurrences of rheumatic years that had elapsed since the last rheumatic episode. Rheumatic fever, according to criteria for diagnosis previously defined,9 developed in a total of 14 or 18 per cent of the 77 patients observed during and following a streptococcal infection. The attack rate according to the number of years that had elapsed since the last rheumatic episode was 27, 22, and 12 per cent for less than 5, 5 to 9, and 10 or more years of freedom, respectively. Although the total number of cases studied was small, it is apparent that susceptibility to a recurrence following a streptococcal infection did not decrease greatly as the period of freedom from activity increased. Certainly, one should not discontinue the prophylactic regimen just because a recurrence had not been observed for a period of 5 or 10 years.* It has been suggested that in the adult protection from recurrences might be obtained by treatment of the streptococcal infection. The data presented in table 6 show that reliance on this method is not justified. In this study, 139 patients with a past history of rheumatic fever received treatment for the respiratory illness with antibiotics and were followed for signs of recurrences. All these patients exhibited exudative tonsillitis or pharyngitis and cul-* It is possible that freedom from experience with the group A streptococcus afforded by prophylaxis for a period of 5 or more years may alter the attack rate after a proved streptococcal infection, but no data are available for analysis. In summary, rheumatic recurrences occur in adult life in spite of freedom from activity for many years and the risk of recurrent activity in adult life following a streptococcal infection is high. Therefore, the risk of a recurrent attack of acute rheumatic fever in adults depends primarily on effective contacts with a carrier of the group A streptococcus. Thus, estimation of the risk of recurrence of rheumatic fever is an individual problem and the decision as to how long prophylaxis should be continued must be based on many factors. In the opinion of the authors, it is mandatory to continue prophylaxis as long as the patient is in school or serving in the armed services. Likewise, the adult, especially the parent, who is exposed to children should be protected. Those whose occupations demand intimate exposure to many people undoubtedly experience an increased risk. In contrast, a chauffeur-driven executive who is exposed to few people, other than his secretary and other chauffeur-driven executives, has less opportunity to contract infection. All these variable and individual factors must be considered by the physician in making the decision as to how long prophylaxis should be continued in an individual patient. It is not sufficient to rely on antibiotic treatment of a streptococcal infection, since many are inapparent or cause few symptoms and therapy does not prevent all recurrences. In addition, there is still some doubt whether therapy of the respiratory infection prevents cardiac damage. Therefore, prophylaxis should be maintained indefinitely except in those few individuals in whom the risk of contracting a streptococcal infection is negligible.
